Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia

Michaela Prochazkova1, Anita Terse1, Niranjana D Amin2, Bradford Hall1, Elias Utreras1,3, Harish C Pant2 and Ashok B Kulkarni1*

Abstract

Background: Cyclin-dependent kinase 5 (Cdk5) is a unique member of the serine/threonine kinase family. This kinase plays an important role in neuronal development, and deregulation of its activity leads to neurodegenerative disorders. Cdk5 also serves an important function in the regulation of nociceptive signaling. Our previous studies revealed that the expression of Cdk5 and its activator, p35, is upregulated in nociceptive neurons during peripheral inflammation. The aim of the present study was to characterize the involvement of Cdk5 in orofacial pain. Since mechanical hyperalgesia is the distinctive sign of many orofacial pain conditions, we adapted an existing orofacial stimulation test to assess the behavioral responses to mechanical stimulation in the trigeminal region of the transgenic mice with either reduced or increased Cdk5 activity.

Results: Mice overexpressing or lacking p35, an activator of Cdk5, showed altered phenotype in response to noxious mechanical stimulation in the trigeminal area. Mice with increased Cdk5 activity displayed aversive behavior to mechanical stimulation as indicated by a significant decrease in reward licking events and licking time. The number of reward licking/facial contact events was significantly decreased in these mice as the mechanical intensity increased. By contrast, mice deficient in Cdk5 activity displayed mechanical hypoalgesia.

Conclusions: Collectively, our findings demonstrate for the first time the important role of Cdk5 in orofacial mechanical nociception. Modulation of Cdk5 activity in primary sensory neurons makes it an attractive potential target for the development of novel analgesics that could be used to treat multiple orofacial pain conditions.

Keywords: Cdk5, p35, Trigeminal ganglia, Orofacial pain, Mouse model

Background

Orofacial pain affects millions of people worldwide. It is characterized by throbbing, sharp or burning pain in the head, neck, face, mouth, gums or teeth. Epidemiological studies indicate that orofacial pain occurs in approximately 10% of the adult population [1], and women are more often affected than men by a ratio of 2:1 [2]. Orofacial pain episodes are usually very debilitating for the patient. However, relatively few studies are focused on characterizing orofacial pain, particularly due to the limited number of animal models available to study nociception in the trigeminal region. Most of these models have been adapted from those used for studying peripheral pain and are primarily based on the induction of inflammation by the administration of nociceptive agents, such as complete Freund’s adjuvant [3,4], carrageenan [5,6], and formalin [7-10]. Other models are based on the direct damage to a nerve (cutting, ligating, or crushing) [11-14]. These models suffer from certain limitations, such as variation in subjective observation, inability to escape from the noxious stimulus, and induction of the stress in a test animal. The recently reported operant behavioral assay using a reward-conflict paradigm wherein a test animal can decide between receiving a reward or escaping an aversive stimulus present new perspectives on measuring pain in the orofacial region [15-18].

There is accumulating evidence that protein kinases are involved in mediating several types of pain. Cdk5 is a serine/threonine kinase widely distributed in different mammalian tissues, but its kinase activity is observed...
primarily in neuronal cells, due to the selective expression of its activators, p35 and p39. Cdk5 plays important roles in many vital processes, including brain development and function, neuronal migration, neurotransmitter release, cell adhesion and survival, drug addiction, learning, memory [19-23], and also in many non-neuronal functions [24-26]. Cdk5 knockout mice are embryonic lethal with numerous lesions in the central nervous system [27]. Efforts to delineate molecular roles of Cdk5 in vivo led to the generation of mice overexpressing [28] or lacking [29] p35, an activator of Cdk5. Recently, we and others discovered that Cdk5 activity regulates peripheral pain signaling, and that it is required for the basal responses to noxious heat [30,31]. The p35 knockout mice (with residual Cdk5 activity) showed delayed responses to painful thermal stimulation (hypoalgesia), whereas mice overexpressing p35 (with significantly increased Cdk5 activity) were more sensitive to painful thermal stimulation showing hyperalgesia. Moreover, we have identified that the expression of p35, as well as Cdk5 kinase activity, is present in the dorsal root ganglia and trigeminal ganglia neurons, and both are significantly increased upon the induction of peripheral inflammation [32]. Furthermore, nociceptor-specific Cdk5 conditional knockout mice developed hypoalgesia associated with reduced phosphorylation of the TRPV1 channel [30].

The goal of the current study was to evaluate the role of Cdk5 in orofacial mechano-sensation and to characterize the behavioral changes of mice lacking or overexpressing p35 using adapted orofacial stimulation test (Additional file 1).

Results

Cdk5 activity in transgenic p35 (Tgp35) and p35 knockout (p35−/−) mice

We initially examined the expression and activity of Cdk5/p35 in the trigeminal ganglia, brainstem, and brain of mice that overexpress or lack p35. Analysis of the Tgp35 mice revealed a significant increase in p35 mRNA (Figure 1A) as well as in p35 protein levels (Figure 1B). There was a three-fold increase in Cdk5 activity (Figure 1C) in the trigeminal ganglia of Tgp35 mice compared with the wild-type (WT) mice (p < 0.001). The Tgp35 mice also showed a significant increase in p35 mRNA and protein levels as well as in Cdk5 activity in brainstem and in brain (Figure 1A-C). The analysis of the p35−/− mice showed almost undetectable p35 mRNA and protein levels (Figure 2A and B) and significantly decreased Cdk5 activity (Figure 2C) in tissue homogenates from the trigeminal ganglia, brainstem, and brain, as compared to controls (p < 0.001). The p35 expression levels and Cdk5 activity correlated with the mouse genotype, thus confirming that the p35 level is the limiting factor for the Cdk5 activity [28].

Normal motor coordination and locomotion in Tgp35 and p35−/− mice

Having established the p35 expression levels and the Cdk5 activity in Tgp35 and p35−/− mice, we determined whether this difference in expression and activity of Cdk5/p35 could affect the motor coordination and locomotion of these genetically modified animals. We did not observe any motor deficit using the acceleration test with rotarod when the rotation was set to accelerate from 4 to 40 rpm during the defined period of time. The average latency to drop from the cylinder was 269 seconds in Tgp35 and 274 seconds in wild-type FVBN control mice, respectively (Additional file 2A). Similarly, no significant difference in the fall latency was observed in p35−/− mice (average latency 253 seconds in p35−/− and 256 seconds in the wild-type C57 controls) (Additional file 2A). There were no significant differences in the fall latency during the testing using the constant rotation speed. The p35−/−, Tgp35, and their respective, wild-type controls showed no motor deficits as evident from the mean time spent on the rotarod (Additional file 2B).

Normal anxiety level and exploratory behavior in Tgp35 and p35−/− mice

Before performing the orofacial operant assay on these mice, we also assessed anxiety, exploratory activity, and stereotypical behavioral using the open-field test. Neither horizontal (Additional file 2C) or vertical (Additional file 2D) activity was affected in the p35−/− or Tgp35 mice, in comparison to the control mice. Since the middle of a non-familiar arena is anxiogenic for rodents, anxiety was studied by analyzing the time spent and total distance travelled in the middle of the cage. There were no significant differences in the time spent in the center of the cage as well as the center distance travelled by the Tgp35 and their littermate controls (Additional file 3A), and the p35−/− and wild-type C57 mice controls (Additional file 4A). There were also no significant changes in the stereotypical behavioral (Additional file 3B and Additional file 4B) or time spent at the different corners of the activity cage (Additional file 3C and Additional file 4C), indicating that the difference in the p35 levels did not cause any change in anxiety or exploratory behavior of the mice.

Normal baseline behavior in orofacial operant assay

It was previously reported that the reward conflict paradigm (using parameters such as reward licking events, facial contact events, and facial contact duration) could serve as a characteristic marker of pain in the orofacial area [15,16]. In the mouse orofacial operant assay that we report here, the number of attempts the test mouse made to acquire the reward and the duration that it
Figure 1 (See legend on next page.)
spent acquiring the reward were the basic outcomes for this behavioral testing. Naïve animals were initially trained to access the reward through the drinking window with an innocuous module. During the baseline measurements, the Tgp35 and WT FVBN control mice did not show any aversive behavior, and there was no difference in the number of beam breaks and time the animals spent with the licking recorded (Figure 3A). After the completion of five different training sessions, we observed the effects of the mechanical stimuli on orofacial outcome measures.

**Mechanical hyperalgesia in Tgp35 mice**

In the presence of mechanical stimulators, the Tgp35 mice showed aversive behavior to mechanical stimuli as indicated by a decrease in the number of attempts to access the reward and the contact time compared to the WT FVBN mice. The Tgp35 mice exhibited significant mechanical hyperalgesia when subjected to orofacial stimulation using plates with either 6 + 6 wires (Figure 3B), 9 + 9 wires (Figure 3C), or 13 + 13 wires (Figure 3D). The Tgp35 mice made significantly fewer attempts to acquire the reward and spent much less time licking the reward compared to the wild-type controls ($p < 0.001$). The mechanical hyperalgesia caused by the plates with the highest number of wires produced a significantly lower reward intake as well as reduction in the licking time, compared to the plates with the lower numbers of the wires. We determined that the specific behavioral changes between the Tgp35 and the wild-type mice in the licking episodes were caused by the induction of nociception in the trigeminal area (Figure 3A-D).

**Mechanical hypoalgesia in p35 knockout mice**

Similar to the Tgp35 mice, there were no changes in the baseline reward licking paradigm in the p35−/− mice compared with the wild-type C57 control mice (Figure 4A). However, we found that the p35−/− mice displayed a significant mechanical hypoalgesia as compared to the wild-type mice when tested with the plate containing 6 + 6 wires (Figure 4B; $p < 0.001$). An additional noxious stimulus caused a significant decrease in the number of attempts to get the reward and time spent licking reward by the wild-type control mice compared to the p35−/− mice (Figure 4C; $p < 0.001$). The most obvious difference was noticed using the plate with the highest number of the wires. The wild-type mice spent only 1.7 seconds licking, whereas the p35−/− mice licked for more than 13 seconds, indicating much lower pain sensation in the p35−/− mice (Figure 4D; $p < 0.001$). The number of attempts and the licking time decreased significantly in the case of the wild-type mice over the entire test period. However, there were no changes in the licking patterns of the p35−/− mice after inducing the mild pain, and more obvious changes were observed inducing more painful conditions. In comparing the wild-type and the p35−/− mice, there were also clear changes in the licking pattern episodes caused by different noceceptive stimulation (Figure 4A-D).

**Discussion**

The present study shows that Cdk5 has an important role in orofacial pain signaling, and that this kinase is associated with mechanical nociception in the mouse vibrissal pad. We utilized two sets of mice with significantly altered Cdk5 activity to confirm its association with orofacial pain. Both p35 knockout (with residual Cdk5 activity) and transgenic p35 (with significantly increased Cdk5 activity) mice depicted an altered response towards the mechanical stimulation. When tested with mechanical stimuli, the mice lacking the p35 gene showed hypoalgesia, whereas the mice overexpressing p35 hyperalgesia. Thus, these results clearly establish a correlation between Cdk5 activity and mechanical nociception.

Since the discovery of Cdk5, numerous studies have revealed its multifunctional roles in important physiological processes, such as brain development and function, neuronal migration, synaptic plasticity, memory, learning, and neurodegenerative disease processes [19-23,26,33]. Our previous studies demonstrated that p35, as well as Cdk5, are expressed in the dorsal root and the trigeminal ganglia, and that the expression and activity of Cdk5/p35 is increased during the inflammation. We and others have also reported that Cdk5 is required for the basal responses to noxious heat [30,31]. The p35 knockout mice showed delayed responses to the painful thermal stimulation whereas the mice
Figure 2 Analysis of the p35 expression profile in p35 knockout mice. The p35 expression levels and Cdk5 activity in the trigeminal ganglia, brainstem, and brain of the p35 knockout mice: (A) q-PCR analysis revealed significantly decreased levels of p35 mRNA in the trigeminal ganglia, brainstem, and brain of the p35 knockout mice. Each data set was normalized to the expression seen in control wild-type animals. Results obtained from four different animals are expressed as mean ± SEM and analyzed by an unpaired t-test (***p < 0.001). (B) Representative Western blots showing p35 protein levels from p35 knockout mice together with corresponding, densitometric analysis. Data were normalized to the levels of p35 in wild-type controls, and are presented as mean ± SEM (unpaired t-test, ***p < 0.001). (C) Cdk5 activity in the trigeminal ganglia, brainstem, and brain of the p35 knockout mice. Data are presented as mean ± SEM and analyzed by an unpaired t-test (**p < 0.01, ***p < 0.001).
overexpressing p35 were more sensitive to painful thermal stimulation at the hind paws and tail. Moreover, the inhibition of Cdk5 activity in the cultured DRG neurons attenuates the capsaicin evoked calcium influx, thus indicating a close link between Cdk5 and TRPV1 [30]. This link was further confirmed using the nociceptor-specific Cdk5 conditional knockout mice, which developed thermal hypoalgesia associated with reduced phosphorylation of TRPV1 [30]. In the current study, we extended our analysis to the role of Cdk5 in orofacial pain.

There are several animal models for studying the different types of pain; whether acute or chronic. Despite
this, there is still a paucity of animal models to study orofacial pain, especially in mice. The majority of the behavioral pain tests in the orofacial area are based on pain-related spontaneous behavior. All these tests induce the pain by an injection of various chemicals (formalin, carrageenan, or capsaicin) into the upper lip or the vibrissal pad, and observe licking or grooming behavior. Recent studies use a mouse grimace scale for the measurement of short term nociception [34] or a device that quantifies a gnawing function in the mouse [35].
However, all of the current protocols for studying orofacial pain have many limitations, including variation in subjective observations, inability to escape from a noxious stimulus, and the induction of stress in the test animal. All of these can cause a large variation in the measured results.

The operant behavioral assay developed and introduced by Neubert in 2005 [16] shows that use of a reward-aversion paradigm offers more benefits. This model is based on the reward-conflict paradigm, where the test animal can decide between receiving a reward, or it can escape from the aversive stimulus by which it can control and modify its own behavior. Therefore, as compared to the other orofacial behavioral tests the use of this operant assay reduces the stress in the testing animals, there is a possibility to provide the multiple measurements using the same animal, and most importantly, it is free from investigator bias when it comes to evaluating the results that are recorded automatically. To the best of our knowledge, there is no reported study using orofacial mechanical stimulation test in mice, and we believe our present study will fill this void.

Although there are many common features in pain transduction and processing in the trigeminal and spinal systems, there are key differences in the anatomical and functional features of the primary afferent neurons of the trigeminal ganglia that distinguish them from neurons of the spinal dorsal root ganglia. Recent studies have shown that not only anatomical, but also electrophysiological and pharmacological differences [36-38] of the trigeminal afferents innervating unique target tissues such as meninges, cornea, teeth, oral/nasal mucosa, and the temporomandibular joint. These differences are consistent with our observations. It has been reported that the intrathecal administration of roscovitine, a Cdk5 inhibitor, inhibited Cdk5 activity and attenuated a formalin-induced nociceptive response in rats [39]. However, we did not observe any changes in trigeminal p35 mRNA and protein levels, nor in the Cdk5 activity after the vibrissal formalin injection (data not shown), thus supporting the theory about the differential regulation of nociception at the periphery and in the vibrissal pad.

We do not know the precise molecular mechanism by which Cdk5 activity can affect the orofacial nociception. There are several possibilities. First, the activation of the TRPV1 channel by Cdk5-mediated phosphorylation could participate in this mechanism. The TRPV1 receptor, consistent with its role as a pain regulator, is expressed in the peripheral and central nervous systems involved in pain detection, transmission, and regulation. Phosphorylation and dephosphorylation reactions regulate TRPV1 receptor activity, which is crucial in promoting inflammatory pain [40,41]. There is clear evidence that the TRPV1 channel activation at the periphery is involved in the development of inflammatory thermal hyperalgesia and heat sensitivity [42]. We have also previously reported that Cdk5 modulates thermal, nociceptive signaling through the phosphorylation of TRPV1 at threonine-407 [30]. Another recent study points out that Cdk5 can control TRPV1 membrane trafficking, and thus regulate the heat sensitivity of the nociceptors [43]. Furthermore, the systemic or intrathecal administration of TRPV1 antagonists is effective in reducing both thermal hyperalgesia, as well as mechanical allodynia associated with chronic or neuropathic pain [44-46], which indicates that TRPV1 could play an important role in integrating multiple pain-producing stimuli. More recent studies have uncovered the involvement of TRPV1 in the central mechanical nociception together in connection with the other TRP channel – TRPA1 [47]. Other studies speculate that the central mechanical hyperalgesia could be induced by the functional interaction between P2X3 [48] or NMDA receptor [49] and TRPV1. These studies provide the evidence that TRPV1 channels are important not only for the peripheral pain sensation, but they can also play an important role in the central mechanical nociception.

An interesting possibility is that Cdk5 can mediate orofacial mechanical hyperalgesia through the regulation of the neurotransmitter release, thus indicating that this kinase could be an important presynaptic control parameter. Deregulation of its activity could affect nociception via the presynaptic mechanism with the subsequent initiation of the pain sensation [50-52]. Another possibility is that Cdk5 could mediate the orofacial mechanical hyperalgesia through the activation of other potential mechanotransducers. It is well known that the upregulation of Cdk5 activity can lead to phosphorylation of delta opioid receptor [53,54], NMDA receptor [55,56], P2X3 receptor [57], and voltage gated calcium channels [58]. Additionally, there are other potential candidates like TRPA1 [59-61] or TREK channels [62,63] that contain the Cdk5 phosphorylation consensus sequence and may be involved in the Cdk5-mediated activation and mechanotransduction in the orofacial area. To understand the precise mechanism through which Cdk5 regulates orofacial mechanosensitisation will require further studies; including molecular, electrophysiological, and behavioral methods to map the functional role of Cdk5 in this type of the nociception.

**Conclusions**

We have adapted orofacial stimulation test for mice that could be used for orofacial pain studies, and using this test we have identified that Cdk5 activity has an important role in orofacial mechanical nociception. Moreover, our studies also demonstrate that genetically engineered mice with the altered Cdk5/p35 levels will prove to be
valuable models to identify and characterize the inhibitors of Cdk5/p35 as novel analgesics to treat orofacial pain.

Methods

Animals
The p35−/− mice and the age-matched, wild-type controls were maintained in C57BL6/129SVJ background. Tgp35 mice and the wild-type littermate controls were maintained in FVBN background. All of the animals were housed and bred in standard cages, and they were maintained in climate and light controlled rooms with free access to food and water in accordance with the U.S. National Institutes of Health Guide for Care and Use of Laboratory Animals. All of the experiments adhered to the guidelines of the IASP Committee for Research and Ethical Issue [64].

Rotarod test
The p35−/− and Tgp35 mice were evaluated for motor abilities, coordination, and balance by performance on the rotarod (Model 7650, Ugo Basile, Italy). This instrument consists of a platform under a rotating cylinder that can be set either to accelerate from 4 to 40 rpm in the defined period of time or used at a constant speed. The automated rotarod system has a timer linked to the platform panel onto which the mouse falls (approximately 15 cm below the rotating cylinder). During the testing, the animals have to continuously walk forward to keep from falling off the rotating cylinder. After the mice became familiarized with this procedure, they were placed on the rotating cylinder, and the time until the animal fell down was measured in three different tests performed on three consecutive days.

Open field test
Anxiety, exploratory activity, as well as spontaneous motor activity were evaluated using the VersaMax Animal activity monitoring system (AccuScan Instruments Inc., Columbus, OH, USA). The testing instrument consists of a clear, plexiglass, rectangular cage (42 × 42 × 30 cm), with the transparent side wall. Two sets of sixteen photocells are aligned from the front to back of the cage and from side to side for recording horizontal activity. Vertical activity is assessed by an additional sixteen photocells located above the horizontal cells. The mice were placed individually in the center of the open field apparatus, and their behavior was monitored for ten minutes. Horizontal or vertical activity (rearing measured by counting the number of beam interruptions), time spent in the center area of the open field, and stereotopic counts were automatically recorded using the VersaMax software system.

Mouse orofacial stimulation test
Using a small plastic reducer, we have modified the Orofacial Stimulation Test (31300, Ugo Basile, Italy), which was previously used only for the measurement of hypersensitivity to thermal or mechanical stimulation of the trigeminal area in rats, and adapted it for assessing behavioral responses to mechanical stimulation in mice (Additional file 1C).

An orofacial stimulation test consists of several parts - the plastic cage (26.5 cm wide, 20 cm deep, and 48 cm long) with the interface wall containing a drinking window (1.5 cm wide × 2 cm high) that allows a mouse an access to a reward; an infrared photo beam built on the exterior aspect of the window linked to the ORO software that automatically quantifies feeding behavior by measuring the number of attempts the animals made to acquire the reward, and the total duration of feeding time (Additional file 1A). The equipment is supplemented with metal inserts containing a different number and configuration of the Nitinol wires (0,155 mm) utilized to induce varying degrees of trigeminal, mechanical nociception (Additional file 1B). Each of these metal inserts can be mounted onto the opposite aspect of the drinking window with six screws.

During the orofacial operant assay, the test mouse inserts its snout through the drinking window in the interface wall to access a nozzle of the bottle containing reward (30% sucrose) [65]. Simultaneously, while accessing the nozzle, the mouse breaks an analog output from the infrared detectors (Banner Engineering, Minneapolis, MN, USA) placed directly behind the drinking window, and thus its attempts to get the reward can be recorded and analyzed with the ORO software (Additional file 1D).

The mice were deprived of food and water for at least a period of eight hours prior to the testing sessions, which was done to increase the incentive for reward acquisition. After the completion of tests, access for food and water was restored. The mice were trained and tested in the same cage and at the same time each day, and they had a day of rest between the testing.

Initially, the animals were trained to access the reward through the blank plate (without the wires). For mechanical testing, access to the reward was impeded by inserting the plate with the different number of the wires providing mechanical contact with the vibrissal pad region of the tested animal (Additional file 1D). We used three different plates with 6 + 6, 9 + 9, or 13 + 13 wires at each side in order to apply a different level of mechanical force to the animal vibrissal pad, so as to induce different degrees of pain. After completing five, different, twenty-minute training sessions, the animals were retested three times using each plate with a different number of wires, in increasing order, starting with the lowest to the highest number of wires. The outcome
measures that were collected during the testing consisted of the total duration of time the test mouse spent acquiring the reward over a twenty minute period of time, with or without (baseline measurements) mechanical stimulators and the number of attempts the test mouse made to access the reward. Both were determined automatically by an interruption of an infrared beam when the animal placed its snout through the opening in the interface wall.

Quantitative real-time PCR (q-PCR)
The trigeminal ganglia, brainstem, and the brain were dissected out from p35−/−, Tg p35, and wild-type control mice and these tissues were immediately frozen at −80°C. The total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA, and USA), according to the manufacturer’s instructions. The purity of the RNA was assessed by the ratio of absorbance at 260 nm and 280 nm. The RNA from each sample was reverse transcribed using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The q-PCR reactions were conducted using cDNA, specific primers (Assays on Demand Gene Expression Products), and TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), and they were run in duplicates using the Real-time PCR System 7500 (Applied Biosystems, Foster City, CA, USA). The p35 mRNA levels were normalized to the levels of HPRT using the comparative cycle threshold (ct) method.

Antibodies
Anti-p35 (C19), Anti-Cdk5 (C8) and secondary horseradish peroxidase-conjugated anti-mouse and anti-rabbit antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The anti α-tubulin antibody was purchased from Sigma Aldrich (Sigma-Aldrich, St. Louis, MO, USA).

Western blotting
The tissue homogenates were lysed in tissue protein extraction reagent (Thermo Scientific, Rockford, IL, USA) containing a cocktail of protease (Complete Mini, Roche, Indianapolis, IN, USA) and phosphatase (PhosSTOP, Roche, Indianapolis, IN, USA) inhibitors to avoid degradation of the proteins. After thirty minutes of incubation on ice, the samples were spun down at 14000 rpm at 4°C for 30 min. The supernatant was assayed for total protein concentration using the Bradford Protein Assay (Bio-Rad, Hercules, CA, USA). The proteins were denatured by boiling them with NuPAGE LDS sample buffer and NuPAGE sample reducing agent (Invitrogen, Carlsbad, CA, USA) for 10 min. Each sample was separated by 4-12% SDS PAGE gels (Invitrogen, Carlsbad, CA, USA) and transferred to 0.45 μm nitrocellulose membrane (Invitrogen, Carlsbad, CA, USA). The blots were blocked for 1 h in phosphate buffered saline containing 5% nonfat dry milk and 0.05% Tween20 (Sigma-Aldrich, St. Louis, MO, USA), and then they were blotted with primary antibodies overnight at 4°C. The membranes were then probed with horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG at room temperature for one hour, and then they were finally developed by SuperSignal West Pico or Dura Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA). The immunoblots were analyzed by densitometry using ImageJ analysis system software.

Immuno-precipitation and Cdk5 activity assay
Immuno-precipitation and Cdk5 kinase activity were performed as described previously [66]. Briefly, the protein G (+) A-agarose beads were washed three times with tris-buffered saline (TBS) and incubated with Cdk5 antibody (1–2 μg/500 μg of protein lysate, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature with gentle mixing. The beads were centrifuged and washed three times with TBS and then suspended in TBS. The protein lysates from the trigeminal ganglia, brainstem, and brain were incubated with antibody conjugated beads for 2 h and 30 min at 4°C on a rotating wheel. The beads were subsequently centrifuged and washed two times with TBS, one time with 1X kinase buffer and suspended in kinase buffer (50 mM Tris/HCl pH 7.4, containing 1 mM EGTA, and 5 mM MgCl2). The immunoprecipitated beads were used as an enzyme source for the kinase activity. For the kinase assay, a total volume of 50 μL of kinase assay mixture was used, containing 50 μM Tris/HCl (pH 7.4) with EGTA, 1 mM dithiothreitol, 5 mM MgCl2, 10 μg of histone H1, and 10 μL of Cdk5 immunoprecipitates. The phosphorylation reaction was initiated by the addition of 0.1 mM [γ-32P] ATP and incubated at 30°C for one hour. The reaction was stopped by the addition of the Laemmli sample buffer. The reaction mixture was heated for five minutes at 90°C and electrophoresed on a 4-20% SDS-PAGE gel stained with Coomassie blue, and then dried and exposed overnight for the detection of 32P-labeled Histone H1 by autoradiography. The films were scanned, and the bands were quantified using ImageJ software.

Statistical analysis
All data are expressed as a mean ± SEM. The statistical evaluation was done with GraphPad Prism software, version 5.0 (GraphPad, San Diego, CA, USA). Statistical differences between the experiments were assessed by unpaired t-test. The significance level was set at p < 0.05.
Additional files

Additional file 1: Mouse orofacial stimulation test system used for the measurement of orofacial mechanical nociception. (A) Orofacial stimulation test device. (B) The mechanical inserts with different number of wires used for the induction of trigeminal pain. (C) The plastic reducer used for the modification of the existing system to be applicable for the characterization of mouse orofacial pain. (D) An example showing the mouse during the reward licking while its vibrissal region is in direct contact with the wires.

Additional file 2: Effect of different p35 genotype on locomotor and exploratory activity. (A) The mean performance time determined as time spent on the rotating cylinder during the acceleration. (B) The latency to fall from the rotating cylinder by the constant speed. (C) The unafected horizontal and (D) vertical activity as revealed by the open field test. The data analyzed by the unpaired t-test are expressed as mean ± SEM and represent the mean from four different animals.

Additional file 3: The effect of upregulated p35 and Cdk5 activity on mouse behavior in an open-field test. (A) The center distance travelled and time spent in the activity cage, (B) stereotopy and the time Tgp35 mice spent with the stereotypic behavior. (C) The time Tgp35 mice spent in the different parts of the activity cage during ten minutes of measurement. These values represent the mean ± SEM from four animals.

Additional file 4: The effect of downregulated p35 and Cdk5 activity on mouse behavior in an open-field test. (A) The center distance travelled and time spent in the center of the activity cage, (B) stereotopy and the time p35 knockout mice spent with the stereotypic behavior. (C) The time p35−/− mice spent in the different parts of the activity cage during 10 min of measurement. These values represent the mean ± SEM from four animals.

Abbreviations

Cdk5: Cyclin-dependent kinase 5; TRPV1: Transient receptor potential vanilloid 1; TG: Trigeminal ganglia; Tgp35: Transgenic p35 mice; p35−/−: p35 knockout mice; q-PCR: Quantitative real-time PCR; WT: Wild-type.

Competing interest

The authors declare that they have no conflict of interest.

Authors’ contributions

MP and ABK designed the experiments. MP, AT, EU, BH, and NDA performed research; MP, AT, EU, BH, NDA, HCP and ABK analyzed data, and MP and ABK wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the Divisions of Intramural Research, National Institute of Dental and Craniofacial Research and the National Institute of Neurological Disorders and Stroke, National Institutes of Health. We would like to thank Drs. Michael Iadarola, Jason Keller, Santosh Mishra, and Varsha Shukla for their helpful discussions during the course of these studies, and Mr. Larry Jones for his expert editorial assistance.

Author details

1Functional Genomics Section, Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA. 2Laboratory of Neurochemistry, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA. 3Laboratory of Cellular and Neuronal Dynamics, Faculty of Science, University of Chile, Santiago, Chile.

Received: 13 August 2013 Accepted: 17 December 2013 Published: 21 December 2013

References

1. Maidland G, Newton-John T, Feinmann C: Chronic idiopathic orofacial pain: Is what is the evidence base? Br Dent J 2001, 191:22–24.

2. Kohlmann T: Epidemiology of orofacial pain. Schmerz 2002, 16:339–345.

3. Romero-Reyes M, Akerman S, Nguyen E, Wijeswarapu A, Horn B, Dong HW, Charles AC: Spontaneous behavioral responses in the orofacial region: a model of trigeminal pain in mouse. Headache 2013, 53:137–151.

4. Yasuda M, Shinoda M, Kyomoto M, Honda K, Suzuki A, Tamagawa T, Kaji K, Kimoto S, Iwas K: P2X3 receptor mediates ectopic mechanical allodynia with inflamed lower lip in mice. Neurosci Lett 2012, 528:67–72.

5. Poh KW, Lustun N, Manikandan J, Ong WY, Yeo JF: Global gene expression analysis in the mouse brainstem after hyperalgesia induced by facial carrageenan injection—evidence for a form of neurovascular coupling? Pain 2009, 142:133–141.

6. Poh KW, Yeo JF, Stohler CS, Ong WY: Comprehensive gene expression profiling in the prefrontal cortex links immune activation and neutrophil infiltration to antinociception. J Neurosci 2012, 32:45–45.

7. Bohnhor M, Ihmsen H, Schwilden H, Yeomans DC, Tzabaiz A: The orofacial formalin test in mice revisited—effects of formalin concentration, age, morphology and analysis method. J Pain 2011, 12:633–639.

8. Lucchinri P, Childeric A, Gaydier AM, Voisin D, Dallet R: The orofacial formalin test in the mouse: a behavioral model for studying physiology and modulation of trigeminal nociception. J Pain 2006, 7:908–914.

9. Miranda HF, Noriega V, Sierralet F, Prieto JC: Interaction between desipramine and desferroxamine in the orofacial formalin test in mice. Pharmacoel Biochem Behav 2011, 97:423–427.

10. Miranda HF, Noriega V, Zepeda RJ, Sierralet F, Prieto JC: Systemic synergism between codeine and morphine in three pain models in mice. Pharmacoel Rep 2013, 65:80–88.

11. Cha M, Kohan KJ, Zuo X, Ling JX, Gu J: Assessment of chronic trigeminal neuropathic pain by the orofacial operant test in rats. Behav Brain Res 2012, 234:82–90.

12. Krzyzanowska A, Pottolo S, Cabrero M, Sanchez-Lopez J, Krishnasamy S, Venero C, Avendano C: Assessing nociceptive sensitivity in mouse models of inflammatory and neuropathic trigeminal pain. J Neurosci Methods 2011, 201:56–64.

13. Rossi HL, Jenkins AC, Kaufman J, Bhat-Chattreya I, Carle R, Neubert JK: Characterization of bilateral trigeminal constriction injury using an operant facial pain assay. Neuroscience 2012, 224:294–306.

14. Teodoro FC, Tronco Junior MF, Zamponrio AR, Martinez AC, Raa GA, Chichorro JG: Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models. Neurotherapeutics 2013, 47:199–206.

15. Neubert JK, King C, Malphrus W, Wong F, Weaver JP, Jenkins AC, Rossi HL, Carle RM: Characterization of mouse orofacial pain and the effects of lesioning TRPV1-expressing neurons on operant behavior. Mol Pain 2008, 4:43.

16. Neubert JK, Widmer GC, Malphrus W, Rossi HL, Vierck CJ Jr, Carle RM: Use of a novel thermal operant behavioral assay for characterization of orofacial pain sensitivity. Pain 2005, 116:386–395.

17. Nolan TA, Hester J, Bokrand-Donatelli V, Carle RM, Neubert K: Adaptation of novel operant orofacial testing system to characterize both mechanical and thermal pain. Behav Brain Res 2011, 217:477–480.

18. Rossi HL, Vierck CJ Jr, Carle RM, Neubert JK: Characterization of cold sensitivity and thermal preference using an operant orofacial assay. Mol Pain 2006, 2:57.

19. Dharwali FA, Rajadhyaksha MS: An unusual member of the Cdk family. Cdk5. Cell Mol Neurobiol 2008, 28:351–369.

20. Dhavan R, Tsal LH: A decade of CDK5. Nat Rev Mol Cell Biol 2001, 2:249–759.

21. Lalliot V, Pulido D, Sandoval IV: Cdk5, the multifunctional surveyor. Cell Cycle 2010, 9:384–311.

22. Lieb J, Furst, Vollmar AM, Zahler S: Twice switched at birth: cell cycle-independent roles of the “neuron-specific” cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells. Cell Signal 2011, 23:1698–1707.

23. Su SC, Tsal LH: Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol 2011, 27:485–491.

24. Arti A: Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5. Biochem Pharmacol 2012, 84:985–993.

25. Contreas-Vallejos E, Utreras E, Gonzalez-Billault C: Going out of the brain: Extraneuronal roles of cyclin-dependent kinase 5. Cell Signal 2012, 24:44–52.

26. Rosales JL, Lee KY: Extraneuronal roles of cyclin-dependent kinase 5. Bioessays 2006, 28:1023–1034.
27. Ohshima T, Ward JM, Huh CG, Longnecker G, Veerrana, Pant HC, Brady RO, Martin LJ, Kulkarni AB: Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 1996, 93:11173–11178.

28. Takahashi S, Ohshima T, Cho A, Sreenath T, Iadecola MJ, Pant HC, Kim Y, Naim AC, Brady RO, Geerband P, Kulkarni AB: Increased-mediated dopaminergic signaling. Proc Natl Acad Sci USA 2005, 102:1737–1742.

29. Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai HL: Mice lacking p35, a neuronal specific activator of Cdk5, display cortical laminar defects, seizures, and adult lethality. Neuron 1997, 18:29–42.

30. Pareek TK, Keller J, Kesavapany S, Pant HC, Iadecola MJ, Brady RO, Kulkarni AB: Cyclin-dependent kinase 5 regulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1. Proc Natl Acad Sci USA 2007, 104:6660–6665.

31. Yang YR, He Y, Zhang Y, Li Y, Li Y, Han Z, Hu H, Wang Y: Activation of cyclin-dependent kinase 5 (Cdk5) in primary sensory and dorsal horn neurons by peripheral inflammation contributes to heat hyperalgesia. Pain 2007, 127:109–120.

32. Pareek TK, Keller J, Kesavapany S, Pant HC, Iadecola MJ, Brady RO, Kulkarni AB: Cyclin-dependent kinase 5 activity regulates pain signaling. Proc Natl Acad Sci USA 2006, 103:791–796.

33. Maccioni RB, Orth C, Concha IL, Munoz JP: The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer’s disease. Eur J Biochem 2001, 268:1518–1527.

34. Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, Glick MS, Ambalavanar R, Okita C, Concha IL, Munoz JP: Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of the cloned capsaicin receptor vanilloid 1. Neuron 1998, 26:933–944.

35. Dolan JC, Lam DK, Achnijsn SH, Schindler BM: The dolognometer: a novel instrument and assay to quantify nociception in rodent models of orofacial pain. J Neurosci Methods 2010, 197:205–217.

36. Ambalavanar R, Montani D, Desprès C, Furth SC, Gage FH, Steinert PM, Despres D, Steinert PM: The role of heat sensitivity of nociceptors through KIF13B. Cyclin-dependent kinase 5 controls TRPV1 membrane trafficking and integrates multiple pain-producing stimuli. Proc Natl Acad Sci USA 2005, 102:1737–1742.

37. Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, Glick MS, Ambalavanar R, Okita C, Concha IL, Munoz JP: Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1. Proc Natl Acad Sci USA 2007, 104:6660–6665.

38. Harriott AM, Gold MS: Electrophysiological properties of dorsal afferents in the absence and presence of inflammatory mediators. J Neurophysiol 2009, 101:3126–3134.

39. Wang CH, Chou WY, Hung KS, Jawan B, Lu CN, Liu JK, Hung YP, Lee TH: Intrathecal administration of rosiglitazone inhibits Cdk5 activity and attenuates formalin-induced nociceptive response in rats. Acta Pharmacol Sin 2005, 26:46–50.

40. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816–824.

41. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D: The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998, 21:531–543.

42. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D: Sensory-specific expression of neuronal cyclin-dependent kinase-5 by staurosporine and purine agonists. Eur Biophys J 2006, 35:1005–1108.

43. Watabiki T, Kiso T, Tsukamoto M, Aoki T, Matsuzaka N: Intrathecal administration of A51928370, a transient receptor potential vanilloid 1 antagonist, attenuates mechanical allodynia in a mouse model of neuropathic pain. Mol Pharmacol 2011, 84:1105–1108.

44. Yu L, Yang F, Luo H, Liu FY, Han JS, Xing GG, Wan Y: The role of TRPV1 in different subtypes of dorsal root ganglion neurons in rat chronic inflammatory nociception induced by complete Freund’s adjuvant. Mol Pain 2008, 4:51.

45. Ro YJ, Lee JS, Zhang Y: Activation of TRPV1 and TRPA1 leads to muscle nociception and mechanical hyperalgesia. Pain 2009, 144:270–277.

46. Saloman JL, Chung MK, Ro YJ: P2X (3) and TRPV1 functionally interact and mediate sensitization of trigeminal sensory neurons. Neuroscience 2012, 223:226–238.

47. Lee J, Saloman JL, Weltland G, Auh QS, Chung MK, Ro YJ: Functional interactions between NMDA receptors and TRPV1 in trigeminal sensory neurons mediate mechanical hyperalgesia in the rat masseter muscle. Pain 2012, 153:1514–1524.

48. Kim SH, Ryan TA: Cdk5 serves as a major control point in neurotransmitter release. Neurotoxin 2010, 67:797–809.

49. Kim SH, Ryan TA: Balance of calcineurin alpha and Cdk5 activities sets threshold for trigeminal nociceptors to respond to chemosensory stimuli. Proc Natl Acad Sci USA 2012, 109:46666–46672.

50. Chen HJ, Xie WY, Hu F, Zhang Y, Wang J, Wang Y: Disruption of delta-opioid receptor phosphorylation at threonine 161 attenuates morphine tolerance in rats with CFA-induced inflammatory hypersensitivity. Neurosci Bull 2012, 28:162–169.

51. Xie WY, He Y, Yang YR, Li YF, Kang K, Xing BM, Wang Y: Disruption of Cdk5-associated phosphorylation of residue threonine-161 of the delta-opioid receptor: impaired receptor function and attenuated morphine antinociceptive tolerance. J Neurosci 2009, 29:3511–3564.

52. Zhang R, Liu Y, Zhang J, Zheng Y, Gu X, Ma Z: Intrathecal administration of rosiglitazone attenuates cancer pain and inhibits the expression of NMDA receptor 2B subunit mRNA. Proc Biochem Behav 2012, 101:19–45.

53. Nair A, Simonetti M, Fabbretti E, Nistri A: The Cdk5 kinase downregulates ATP-gated ionotropic P2X3 receptor function via serine phosphorylation. Cell Mol Neurobiol 2010, 30:505–509.

54. Tomiwa K, Ohata J, Matsutaka M, Moriwaki A, Li ST, Takei K, Matsui H: Cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia. Pain 2009, 144:270–277.

55. Alloui A, Zimmermann K, Mamet J, Duprat F, Noel J, Chemin J, Guy N, Neumark A, Niedermayer I, Kornelakis E, et al: Effect of caloric and non-caloric sweet solutions on thermal and mechanical nociception in rodent models of inflammatory pain. Behav Brain Res 2011, 216:723–725.

56. Veeranna A, Shetty KT, Amin N, Grant P, Albers RW, Pant HC: Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-18. Neuronchem Res 1996, 21:629–636.

Cite this article as: Prochazkova et al.: Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia. Molecular Pain 2013 9:66.